Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $90.73.
Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Exelixis, and MacroGenics. According to TipRanks, Lawson has an average return of 5.9% and a 44.19% success rate on recommended stocks.
In addition to Barclays, Blueprint Medicines also received a Hold from Piper Sandler’s Christopher Raymond in a report issued on April 22. However, today, JMP Securities reiterated a Buy rating on Blueprint Medicines (NASDAQ: BPMC).
BPMC market cap is currently $5.65B and has a P/E ratio of -11.02.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in February 2024, Philina Lee, the CCO of BPMC bought 261.00 shares for a total of $488.07.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines (BPMC) Company Description:
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Read More on BPMC:
